Rechercher des projets européens

37 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Heart OMics in AGEing (HOMAGE)

Date du début: 1 févr. 2013, Date de fin: 31 janv. 2019,

As more people survive into old age, the prevalence of heart failure (HF), one of the most common and debilitating diseases in older people, will rise still further. Delaying or preventing HF will have great benefit to those at personal risk, their families, society and the economy. HOMAGE aims to provide a biomarker (BM) approach that will a) help identify i. patients at high risk of developing ...
Voir le projet

 22

 TERMINÉ 

Targets and biomarkers for antiepileptogenesis (EPITARGET)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a comb ...
Voir le projet

 20

 TERMINÉ 

Immune and Neuromodulation Mediated by Alphaherpesviruses (INMA)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2018,

Despite the advances against infectious diseases, morbidity and mortality still pose a very high social and economic impact. Viruses have developed a plethora of strategies to modulate the host. The main goal of my research is to investigate these strategies in order to understand viral immunomodulation, neuromodulation and pathogenesis. This will permit us to develop better intervention approache ...
Voir le projet

 1

 TERMINÉ 

Lymph node homing of immune cells via afferent lymphatics – mechanisms and immune response (LYMPHATICS-HOMING)

Date du début: 1 avr. 2013, Date de fin: 31 mars 2018,

"The continuous migration of immune cells to lymph nodes (LN) is of utmost importance for the induction of both protective immunity as well as immunological tolerance. Despite this pivotal role, little is known regarding migration paths and the molecular cues regulating homing of immune cells that arrive via afferent lymphatic vessels to LN. This conspicuous lack of knowledge is primarily due to p ...
Voir le projet

 1

 TERMINÉ 

Parasite glycobiology and anti-parasitic strategies (GLYCOPAR)

Date du début: 1 déc. 2013, Date de fin: 30 nov. 2017,

"Protozoan parasites and helminths are the cause of some of the most devastating diseases worldwide and a major effort is needed to be able to control or eliminate these diseases. Glycoconjugates are abundant and ubiquitous on the surface of many parasites and they are frequently involved in their survival strategies by forming a protective barrier against host defences. A common feature of the pa ...
Voir le projet

 13

 TERMINÉ 

The effect of intracoronary reinfusion of bone marrow-derived mononuclear cells (BM-MNC) on all-cause mortality in acute myocardial infarction (BAMI)

Date du début: 1 nov. 2011, Date de fin: 31 oct. 2017,

Although the long term prognosis of patients suffering acute myocardial infarction (AMI) has improved since the introduction of reperfusion therapies and primary angioplasty, the 1 year mortality of patients with AMI and resultant left ventricular systolic dysfunction (LVSD) is still as high as 13%. A major reason for the high morbidity and mortality is that the heart has an inadequate regenerativ ...
Voir le projet

 23

 TERMINÉ 

Advances in Small Trials dEsign for Regulatory Innovation and eXcellence (ASTERIX)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

"ASTERIX will contribute towards the expected impact listed in the work program by delivering validated innovative statistical design methodologies for cost efficient clinical trials deriving reliable results from trials in small population groups, especially focusing on rare diseases. It directly addresses the rights of the estimated 30 million European patients suffering from rare diseases to th ...
Voir le projet

 7

 TERMINÉ 

Targeting cardiac fibrosis for heart failure treatment (FIBRO-TARGETS)

Date du début: 1 sept. 2013, Date de fin: 31 août 2017,

The Fibro-Targets project is a multi-disciplinary 4 years program involving 10 partners ambitioning “the identification, characterisation and validation of in vitro and in vivo models of novel therapeutically relevant targets” for myocardial interstitial fibrosis (MIF) in heart failure. The project is based on the hypothesis that the intervention on novel fibrosis-related targets involved in the p ...
Voir le projet

 11

 TERMINÉ 

Quantitative Imaging of Liver Fibrosis and Fibrogenesis (LiverFibrosisImaging)

Date du début: 1 août 2012, Date de fin: 31 juil. 2017,

Chronic liver disease can progress to cirrhosis, with death due to liver failure and cancer. Cirrhosis prevalence in the EU is 0.5%-1%. However, development of therapies that prevent progression to cirrhosis is hampered by the lack of a sensitive, non-invasive method to quantify fibrosis or fibrosis progression (fibrogenesis). Liver biopsy 1) is risky, 2) shows high sampling variability, and 3) is ...
Voir le projet

 3

 TERMINÉ 

European Multicentre Tics in Children Studies (EMTICS)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2017,

This project will undertake pre-clinical and cohort studies that address susceptibility factors for paediatric and adolescent tic disorders, with a particular focus on comorbid obsessive-compulsive symptomatology, from clinical, epidemiological, genetic, microbiological and immunological angles. EMTICS aims to elucidate the complex aetiology of the onset and clinical course of chronic tic disorder ...
Voir le projet

 33

 TERMINÉ 

New Oral Nanomedicines: Transporting Therapeutic Macromolecules across the Intestinal Barrier (TRANS-INT)

Date du début: 1 mai 2012, Date de fin: 30 avr. 2017,

Despite the increasing number of macromolecules with potential impact in the treatment of devastating systemic diseases, these therapies have failed to deliver on their expectations because they cannot be administered in the fashion which is most cost efficient and has the highest patient compliance: the oral route. The availability of an oral form of administration could lead to a great improveme ...
Voir le projet

 20

 TERMINÉ 

Improving the organisation of maternal health service delivery, and optimising childbirth, by increasing vaginal birth after caesarean section (VBAC) through enhanced women-centred care (OPTIBIRTH)

Date du début: 1 sept. 2012, Date de fin: 28 févr. 2017,

Optimal, healthy pregnancy followed by normal birth is the ideal. Caesarean section (CS) doubles the risk of mortality and morbidity (hysterectomy, blood transfusion), and increases the risk of postnatal infection by 5, compared with vaginal birth (WHO Global Survey on Maternal and Perinatal Health). The European Perinatal Health Report (2008) notes “widespread concern” over rising CS rates, which ...
Voir le projet

 11

 TERMINÉ 

Towards Tissue Engineering Solutions for Cardiovascular Surgery (TECAS)

Date du début: 1 janv. 2013, Date de fin: 31 déc. 2016,

"The aim of the TECAS ITN is to integrate the major European contributors in the field of cardiovascular tissue engineering (TE) and regenerative medicine (RM), to generate a coherent framework of expertise which will facilitate the training and career development of early stage researchers (ESRs) in the field. In particular, the intention of this ITN is to focus on the clinical needs of cardiac v ...
Voir le projet

 7

 TERMINÉ 

European clinical study for the application of regenerative heart valves (ESPOIR)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2016,

Acquired and congenital heart disease can necessitate heart valve replacement. However, current heart valve substitutes are not considered ideal as they need anticoagulation, bearing the risk of bleeding when manufactured from non-organic material, or they degenerate when they derive from animals or human tissue donators (homografts) thereby leading to frequent reoperation especially in the young ...
Voir le projet

 15

 TERMINÉ 

Interdisciplinary training network for Tourette Syndrome; structuring European Training capacities for neurodevelopmental disorders (TS-EUROTRAIN)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,

There is a striking lack in structured and standardized training infrastructure for neurodevelopmental disorders across Europe. Such training will be fundamental to promoting standards of care across Europe and will ultimately lead to strategies for the promotion of childhood mental health in Europe. The focus of this Initial Training Network (ITN) is Gilles de la Tourette Syndrome (TS), an inheri ...
Voir le projet

 12

 TERMINÉ 

International study for treatment of childhood relapsed ALL 2010 with standard therapy, systematic integration of new agents, and establishment of standardized diagnostic and research (INTREALL)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2016,

Though survival of children with acute lymphoblastic leukaemia (ALL) has improved, relapse remains a leading cause of mortality in childhood cancer. Given the rarity of the disease, only a large international cooperative group can recruit sufficient patients for prospective studies with specific questions in biologic subgroups. Under the umbrella of the I-BFM SG all relevant mainly European study ...
Voir le projet

 29

 TERMINÉ 

Improving HSCT By Validation Of Biomarkers & Development Of Novel Cellular Therapies (CELLEUROPE)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,

Novel transplant regimens are currently being developed to improve beneficial GvL effects and reduce GvHD and infections via several new forms of cellular therapies. This newly emerging supra-disciplinary field of cellular therapy and regenerative medicine is also being used to improve outcomes in autoimmune disease (such as Rheumatoid Arthritis) and cancers. The goal of this research programme is ...
Voir le projet

 13

 TERMINÉ 

Molecular technology for nuclear imaging and radionuclide therapy (TRACEnTREAT)

Date du début: 1 oct. 2012, Date de fin: 30 sept. 2016,

Cancer is undoubtedly becoming the second largest cause of death in the EU. Future predictions are very somber expecting worldwide 17.5 million deaths and 27 million new cases annually by 2050. New innovative research and properly educated generation of young scientists in fields related to cancer prevention, diagnostics, treatment and management is the only way to ensure progress in solving this ...
Voir le projet

 7

 TERMINÉ 

A novel micronutrient-based strategy to prevent hearing impairments: test and road to market for age-related hearing loss and preservation of residual hearing (PROHEARING)

Date du début: 1 juil. 2012, Date de fin: 30 juin 2016,

Hearing impairment affects 600M people worldwide.  It greatly decreases quality of life, particularly in the elderly, and constitutes an unmet health and medical need.  Regeneration of sensory auditory hair cells is not available as a medical technology.  In concordance with this topic call, we propose a novel strategy based on the development of a new technology, a micronutrient formulation imple ...
Voir le projet

 5

 TERMINÉ 

Markers for Sub-Clinical Cardiovascular Risk Assessemnt (EU-MASCARA)

Date du début: 1 déc. 2011, Date de fin: 31 mai 2016,

EU-MASCARA is a collaborative project that aims to improve diagnosis of cardiovascular diseases and prediction of cardiovascular risk by analysing a panel of biomarkers. EU-MASCARA aims to examine genetic, proteomic and metabolomic markers together with markers of inflammation, oxidative stress and cardiac remodelling to study their incremental diagnostic and predictive value over and above existi ...
Voir le projet

 16

 TERMINÉ 

Advanced Cell-based Therapies for the treatment of Primary ImmunoDeficiency (CELL-PID)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2016,

Primary immune deficiencies (PID) are inherited disorders of the adaptive and innate immune system marked by severe infections, autoimmunity and high risk of cancer. Treatment entails hematopoietic stem cell (HSC) transplantation from allogeneic donors, however in the absence of an HLA compatible donor, HSCT outcome is limited by delayed or suboptimal reconstitution and complications. SCID-X1 and ...
Voir le projet

 20

 TERMINÉ 

Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE)

Date du début: 1 oct. 2011, Date de fin: 31 mars 2016,

Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role in the drive towards personalised medicine remains uncertain.Based on harmonised and standardised European population cohorts we have built significant research collabo ...
Voir le projet

 31

 TERMINÉ 

Neurotrophic Cochlear Implant for Severe Hearing Loss (NeuEar)

Date du début: 1 sept. 2012, Date de fin: 31 déc. 2015,

Sixteen percent of adult Europeans suffer from hearing loss, great enough to adversely affect their daily life. Over the age of 80, 50% of the population is suffering from hearing loss. A large portion of this population is affected by sensoryneural hearing loss (SNHL), a consequence of a progressive degeneration of the primary auditory neurons (ANs), the afferent neurons of the cochlea. These ANs ...
Voir le projet

 6

 TERMINÉ 

HEPATIC MICROFLUIDIC BIOREACTOR (HEMIBIO)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2015,

The goal of HeMiBio is to develop a hepatic microfluidic bioreactor from human iPSC-derived hepatocytes, hepatic sinusoidal endothelial cells (HSEC) and stellate cells (HSC), suitable for inclusion in a repeated dose toxicity testing strategy of pharmaceuticals/cosmetic ingredients. The successful creation of such a liver-device requires (a) homotypic and heterotypic interactions between the three ...
Voir le projet

 13

 TERMINÉ 

Keratinocytes and Matrix metalloproteinases: driving force of skin wound contraction? (WOUND CONTRACTION)

Date du début: 1 déc. 2009, Date de fin: 30 nov. 2015,

Two unconventional concepts of skin contraction are presented that could change the current paradigm of wound healing. The overall objective is to clarify the underlying processes and to develop new therapies to prevent excessive scarring, ameliorate patients lives and reduce medical health care expenses. Specific emphasis lies on the role of Matrix metalloproteinases (MMP) and keratinocytes. Prev ...
Voir le projet

 3

 TERMINÉ 

Multi-scale Biological Modalities for Physiological Human Articulation (MULTISCALEHUMAN)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,

Musculoskeletal diseases (MSD) and related disorders are often considered as an inevitable consequence of aging and they account for the largest fraction of temporary and permanent disability. It is the leading cause of disability in the EU and accounts for more than half of all chronic conditions in people over 50 years of age in developed countries. The burden of MSD and related disorders presen ...
Voir le projet

 7

 TERMINÉ 

Biohybrid templates for peripheral nerve regeneration (Biohybrid)

Date du début: 1 oct. 2011, Date de fin: 30 sept. 2015,

The BIOHYBRID consortium was build up with the overall aim to develop, in a preclinical perspective, an innovative biohybrid artificial nerve device for the regenerative treatment of traumatic injuries of peripheral nerves. This consortium consists of three active and well integrated SMEs as well as seven academic partners that are recognised leaders in the scientific areas of interest for this pr ...
Voir le projet

 10

 TERMINÉ 

From data sharing and integration via VPH models to personalised medicine (p-medicine)

Date du début: 1 févr. 2011, Date de fin: 31 juil. 2015,

Medicine is undergoing a revolution that is transforming the nature of healthcare from reactive to preventive. The changes are catalyzed by a new systems approach to disease which focuses on integrated diagnosis, treatment and prevention of disease in individuals. This will replace our current mode of medicine over the coming years with a personalized predictive treatment . While the goal is clea ...
Voir le projet

 19

 TERMINÉ 

Molecular imaging of the myocardium to facilitate cardiac stem cell therapy (Stem cell imaging)

Date du début: 1 juil. 2011, Date de fin: 30 juin 2015,

In clinical trials, functional benefits of cell therapy for repair of the damaged heart have been moderate and variable. Frequently, only a small fraction of transplanted cells engrafts in injured myocardium. This limits therapeutic efficacy and may explain variability of results. There is a need for improved understanding of therapeutic mechanisms and for improved selection of candidates. Specifi ...
Voir le projet

 1

 TERMINÉ 

Endocannabinoid signaling in heart failure: functional relevance of microRNAs (EnSig-miRNA)

Date du début: 1 août 2011, Date de fin: 31 juil. 2014,

Heart failure is a primary cause of cardiovascular morbidity and mortality with raising economic burden. There is an increasing need for innovative novel therapies. MicroRNAs are novel regulators of gene expression and are implicated in cardiac development and pathologies including heart failure. Research is underway to explore the potential of microRNA-based therapeutics. However many basic resea ...
Voir le projet

 1

 TERMINÉ 

Functional analysis of the neonatal B cell compartment (Neonatal B cells)

Date du début: 1 juin 2010, Date de fin: 31 mai 2014,

Neonatal life is characterized by heightened sensitivity to infectious agents. The sensitivity to infectious diseases is caused by an immaturity of the immunes system which could be due to either qualitative or quantitative differences of neonatal and adult immune cells. In respect to the B cell compartment, several differences have been observed between adults and neonates, including differences ...
Voir le projet

 1

 TERMINÉ 

International Research on Quality in Healthcare (InterQuality)

Date du début: 1 déc. 2010, Date de fin: 30 avr. 2014,

International Research Project on Financing Quality in Healthcare InterQuality gathers the interest for financing systems' effect on quality of healthcare of researchers from seven EU countries and US. The study, based on administrative and survey data, is designed for 36 months. It will take into account needs of four different patient groups (sectors), affected by: hospital, outpatient, pharmace ...
Voir le projet

 10

 TERMINÉ 

Host and viral factors in acute hepatitis C (HEPACUTE)

Date du début: 1 nov. 2010, Date de fin: 30 avr. 2014,

Chronic hepatitis C is one of the most common chronic viral infections of humans and a major cause of chronic liver disease, cirrhosis and liver cancer. Still about 4 million new infections occur world-wide each year with 50-85% of patients progressing to chronic hepatitis C. Currently there is no marker to predict spontaneous viral clearance and to guide treatment decisions.The major objectives o ...
Voir le projet

 17

 TERMINÉ 

Genetic testing in Europe - Network for the further development, harmonization, validation and standardization of services (EUROGENTEST2)

Date du début: 1 janv. 2011, Date de fin: 31 déc. 2013,

EuroGentest is an FP6 European network for the harmonization of genetic testing and for the further improvement of quality in genetic services across Europe.This proposal is to support EuroGentest2, a Coordination Action that will cover the different aspects of quality assurance of genetic practice and has all the ingredients to fulfil the needs. EuroGentest2 will be concerned with setting the tar ...
Voir le projet

 22

 TERMINÉ 

Corline Heparin Technology - Enabling Regenerative Medicine (Corline)

Date du début: 1 avr. 2011, Date de fin: 30 sept. 2013,

Regenerative Medicine (use of cells and tissue to replace or heal impaired functions in the body, RM) is one of the fastest growing areas in today’s medicine, and has the potential to offer treatment to patients with diseases that are currently untreatable. In many new areas of RM there is however a need to improve the outcome of RM concepts and technologies for it to become a viable option to tra ...
Voir le projet

 11

 TERMINÉ 

The impact of Regulation (EC) No 1394/2007 on the development of Advanced Therapy Medicinal Products (ATMPs): an academic perspective (Academic GMP)

Date du début: 1 sept. 2010, Date de fin: 31 mai 2013,

Advanced Therapy Medicinal Products (ATMPs) are medicinal products for human use, based on gene therapy, somatic cell therapy or tissue engineering. A rapidly growing area in translational research, they represent the ‘next generation’ of complex medicines for complex diseases and pose particular challenges to medicines regulation.Regulation (EC) No 1394/2007 has been designed to ensure the free m ...
Voir le projet

 9

 TERMINÉ 

OPTImization of the automated Fitting to Outcomes eXpert with language-independent hearing-in-noise test battery and electro-acoustical test box for cochlear implant users (OPTI-FOX)

Date du début: 1 nov. 2010, Date de fin: 31 oct. 2012,

"Patients suffering from sensori-neural hearing loss caused by damaged hair cells in the cochlea and diagnosed as being profoundly deaf, are potential candidates for cochlear implantation. Today, there are a number of important limitations with respect to the optimal use of these devices in deaf patients. Firstly, cochlear implant speech processors need to be adjusted so that sounds perceived by t ...
Voir le projet

 11